<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383042</url>
  </required_header>
  <id_info>
    <org_study_id>JP-1366-101-FIH</org_study_id>
    <nct_id>NCT03383042</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open-label, Placebo- and Active- Controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jeil Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to investigate the safety, tolerability and pharmacokinetics and
      pharmacodynamics of JP-1366 oral administration in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</time_frame>
    <description>SAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</time_frame>
    <description>SAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</time_frame>
    <description>SAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</time_frame>
    <description>SAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose</time_frame>
    <description>SAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav,ss</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCÏ„</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax,ss</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose</time_frame>
    <description>MAD endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>0-24 hours(Day -1), 0-24 hours(Day 1)</time_frame>
    <description>SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of total time that the intragastric pH was above 4</measure>
    <time_frame>0-24 hours (Day -1), 0-24 hours (Day 1), 0-24 hours (Day 7)</time_frame>
    <description>MAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose</time_frame>
    <description>SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum gastrin concentration</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24h post-dose, Day 4 pre-dose, Day 6 pre-dose, Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose</time_frame>
    <description>MAD</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Anti-Ulcer Agents</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-ascending cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-ascending cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-ascending cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-ascending cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-ascending cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-ascending cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-ascending cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple-ascending cohort 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1 (JP-1366 A mg)</intervention_name>
    <description>Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2 (JP-1366 B mg)</intervention_name>
    <description>Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3 (JP-1366 C mg)</intervention_name>
    <description>Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 4 (JP-1366 D mg)</intervention_name>
    <description>Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 5 (JP-1366 E mg)</intervention_name>
    <description>Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>SAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 6 (JP-1366 F mg)</intervention_name>
    <description>Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>MAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 7 (JP-1366 G mg)</intervention_name>
    <description>Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>MAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 8 (JP-1366 H mg)</intervention_name>
    <description>Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg</description>
    <arm_group_label>Cohort 8</arm_group_label>
    <other_name>MAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged between 19 and 50 at screening

          -  Weight is between 55 and 90 kg and BMI is between 18.0 and 27.0

          -  Those who are adequate to be subjects in this study upon judgment of the investigator
             after physical examination, clinical laboratory test, examination by interview, etc

        Exclusion Criteria:

          -  Subject has clinical significant liver, kidney, nervous system, respiratory,
             endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or
             past history

          -  Subject has gastrointestinal diseases or past history of gastrointestinal diseases
             (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's
             disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of
             study drug, and those who have past history of gastrointestinal surgery (however,
             except simple appendectomy and herniotomy)

          -  Subject has been Helicobacter pylori positive

          -  AST (SGOT) and ALT (SGPT) &gt; 1.5 times to the upper limit of the normal range in
             screening including additional examinations prior to randomization

          -  Subject has anatomical disability in insertion and maintenance of pH meter catheter
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seung Hwan Lee, MD., PhD</last_name>
    <phone>82-2-2072-1920</phone>
    <email>leejh413@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yong Woo Lee, MSC</last_name>
    <phone>82-2-549-4751</phone>
    <email>ywlee97@jeilpharm.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital(SNUH)</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-Gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hwan Lee, M.D., Ph.D.</last_name>
      <phone>82-2-2072-1920</phone>
      <email>leejh413@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seung Hwan Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

